Dr. Michael F. Jardula, MD
Internal Medicine (Internal Medicine Physician)
275 N El Cielo
Palm Springs, CA 92262
Who else practices at this address →
Riverside County includes primary care (1% of residents) and mental health (5% of residents) shortage areas. About shortage areas
At a glance
- Years since graduation
- 42
- In the NPI registry since
- 2005
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license G87344 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Desert Medical Group Inc (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 17 payments worth $391 in total to this clinician.
| Novo Nordisk Inc | $74.14 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $63.34 |
| Viiv Healthcare Company | $58.64 |
| GlaxoSmithKline, LLC. | $46.20 |
| Merck Sharp & Dohme LLC | $32.55 |
| EMD Serono, Inc. | $27.44 |
| Abbott Laboratories | $26.32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.06 |
| Food and Beverage | $391 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $635,089 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - Study name not reported
Novo Nordisk As - ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP)
Abbott Laboratories - A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi
AstraZeneca Pharmaceuticals LP - A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company · Recruiting · NCT07285018 - Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Eli Lilly and Company · Completed · NCT04627038
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.